The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ASH 2017 | Long term follow-up results of rituximab maintenance in elderly MCL patients after first-line immunochemotherapy
The 59th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in Atlanta, GA, on 9–12 December,2017. On Saturday December 9th, an oral abstract session was held on “Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Mantle Cell Lymphoma, New Therapies”. This article is based on data presented at the live session, which may supersede information in the pre-published ASH Abstract.
Abstract #153 was presented during this session, titled “Rituximab Maintenance after First-Line Immunochemotherapy in Mantle Cell Lymphoma: Long-Term Follow-up of the Randomized European MCL Elderly Trial” by Eva Hoster, Department of Medicine III, University Hospital of the Ludwig Maximilians University of Munich, Germany.
Study Highlights
- 560 elderly patients were included in the study with a median age of 70 years (60–87)
- Patients were randomized to receive induction therapy with either 8 cycles of R-CHOP (rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone) or 6 cycles of R-FC (rituximab with fludarabine and cyclophosphamide)
- Patients were then randomized to receive maintenance therapy with either rituximab (R) or interferon-alpha (IFN)
- This study aimed to assess outcomes in elderly MCL patients after long term follow-up (median follow-up = 6.7 years)
Key Findings
- Comparison of R-FC vs R-CHOP induction therapy:
- Cumulative incidence of death without treatment failure: 19% vs 9%, P = 0.0032
- Failure-free survival (FFS) 5-year probability: 31% (95% CI, 25–37) vs 31% (95% CI, 25–37), P = 0.76
- Overall survival (OS) 5-year probability: 42% (95% CI, 36–49) vs 58% (95% CI, 51–64), P = 0.0012
- Comparison of R vs IFN maintenance therapy:
- After R-CHOP 5-year PFS: 51% (95% CI, 40–62) vs 22% (95% CI, 14–32), P < 0.0001
- After R-FC 5-year PFS: 52% (95% CI, 39–63) vs 32% (95% CI, 20–45), P = 0.032
- After R-CHOP 5-year OS: 79% (95% CI, 67–86) vs 59% (95% CI, 48–69), P = 0.0026
- After R-FC 5-year OS: 57% (95% CI, 44–68) vs 54% (95% CI, 39–66), P = 0.60
The study found that therapy with R-CHOP followed by R-maintenance showed significantly increased PFS and OS in elderly MCL patients as first-line therapy. The authors noted that R-FC had a higher cumulative incidence of death from treatment-related complications, which they suggested undermined its value in induction therapy.
References